Cabaletta Bio, Inc. (CABA)
| Market Cap | 313.87M +34.6% |
| Revenue (ttm) | n/a |
| Net Income | -189.51M |
| EPS | -1.37 |
| Shares Out | 215.72M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,594,779 |
| Open | 1.470 |
| Previous Close | 1.500 |
| Day's Range | 1.410 - 1.530 |
| 52-Week Range | 1.180 - 4.230 |
| Beta | 3.54 |
| Analysts | Buy |
| Price Target | 11.75 (+707.56%) |
| Earnings Date | Nov 5, 2026 |
About CABA
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company’s lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, systemic lupus erythematosus, relapsing and progressive multiple sclero... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for CABA stock is "Buy." The 12-month stock price target is $11.75, which is an increase of 707.56% from the latest price.
News
Cabaletta Bio Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference
ACR updates highlighted rese-cel safety and durable responses across autoimmune indications, alongside a launched SSc registrational study. Myositis BLA submission is guided for Q1 2028; a PC-free program update is expected in H1 2027.
Cabaletta Bio price target lowered to $8 from $10 at Citi
Citi lowered the firm’s price target on Cabaletta Bio (CABA) to $8 from $10 and keeps a Buy rating on the shares. The firm updated the company’s model post the…
Cabaletta Bio announces new Phase 1/2 data on rese-cel at ACR Convergence 2026
Cabaletta Bio (CABA) announced new Phase 1/2 clinical data on resecabtagene autoleucel, rese-cel, to be presented in one oral and two poster presentations at the American College of Rheumatology, ACR,...
Cabaletta Bio Presents New Rese-cel Phase 1/2 Clinical Data at ACR Convergence 2026 Featuring Immunomodulator-Free Durability and Favorable Benefit-Risk Profile Across Autoimmune Diseases
100% (6 of 6) of dermatomyositis patients maintained immunomodulator-free, moderate-to-major TIS responses through one year, with most patients also free of steroids
Cabaletta Bio Slides: Corporate presentation
Cabaletta Bio has posted slides in relation to its latest quarterly earnings report, which was published on November 8, 2026.
Cabaletta Bio expects myositis topline results in second half of 2027
Cabaletta Bio (CABA) announced that registrational adult topline results from RESET-Myositis are anticipated in the second half of 2027, with a planned Biologics License Application submission in the ...
Cabaletta Bio Reports Third Quarter 2026 Financial Results and Provides Business Update
RESET-Myositis ® registrational adult topline results anticipated in 2H27 with BLA submission in 1Q28, including Phase 1/2 juvenile dermatomyositis data for potential PRV eligibility and Phase 1/2 adu...
Cabaletta Bio Quarterly report: Q3 2026
Cabaletta Bio has published its Q3 2026 quarterly earnings report on November 5, 2026.
Cabaletta Bio Earnings release: Q3 2026
Cabaletta Bio released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
Cabaletta Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PHILADELPHIA, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching curative targeted cell therapies des...
Cabaletta Bio to Participate in Upcoming Investor Conferences
PHILADELPHIA, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching curative targeted cell therapies des...
Cabaletta Bio Slides: Corporate presentation
Cabaletta Bio has posted slides in relation to its latest quarterly earnings report, which was published on September 29, 2026.
Cabaletta Bio Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Rese-cel, a nine-day autologous CAR T-cell therapy, demonstrates high efficacy and a differentiated safety profile in autoimmune diseases, with no severe neurotoxicity or IEC-HS observed in nearly 100 patients. Durable responses, a scalable manufacturing strategy, and a shift toward preconditioning-free regimens position it as a potential paradigm-shifting therapy.
Cabaletta Bio Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Rese-cel’s nine-day manufacturing process and strong safety profile set it apart in the CAR-T space for autoimmune diseases, with over 90 patients treated and no severe neurotoxicity or IEC-HS events. Key upcoming milestones include pivotal data in scleroderma and myositis, BLA filings, and innovations toward outpatient, preconditioning-free therapy.
Cabaletta Bio reports Q2 EPS (34c), consensus (34c)
“A single infusion of rese-cel has demonstrated the potential to deliver deep, clinical responses after discontinuation of all immunomodulators with up to 1.5 years of follow-up as reported in the…
Cabaletta Bio Earnings release: Q2 2026
Cabaletta Bio released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Cabaletta Bio Quarterly report: Q2 2026
Cabaletta Bio has published its Q2 2026 quarterly earnings report on August 13, 2026.
Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
Registrational RESET-Myositis ® clinical data on track to be reported in mid-2027 to support 2H27 BLA submission for rese-cel
Cabaletta Bio Slides: Corporate presentation
Cabaletta Bio has posted slides in relation to its latest quarterly earnings report, which was published on August 12, 2026.
Cabaletta Bio Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Rese-cel shows durable, immunomodulator-free remissions in myositis and strong safety, enabling outpatient dosing and rapid adoption. Regulatory strategy targets BLA submission in 2H 2027, with potential for a priority review voucher and significant non-dilutive capital.
Cabaletta Bio presents new data for rese-cel in autoimmune diseases
Cabaletta Bio (CABA) announced new clinical data and development updates for its cell therapy, rese-cel, across its autoimmune portfolio at the EULAR 2026 Congress. In the RESET-Myositis study, 83% of...
Cabaletta Bio Transcript: Jefferies Global Healthcare Conference 2026
Rese-cel demonstrated durable efficacy and a strong safety profile across multiple autoimmune diseases, with over 80% of myositis patients meeting primary endpoints and no relapses up to 1.5 years. Outpatient administration and automated manufacturing support scalability and payer alignment.
Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress
83% of dermatomyositis patients in the Phase 1/2 RESET-Myositis study would have met the registrational primary endpoint; all these patients maintained their response off immunomodulators through late...
Cabaletta Bio Slides: Corporate presentation
Cabaletta Bio has posted slides in relation to its latest quarterly earnings report, which was published on June 3, 2026.
Cabaletta Bio Proxy statement: Proxy filing
Cabaletta Bio filed a proxy statement on June 1, 2026, providing details for shareholder voting and corporate governance matters.